Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

New Delhi, As many as eight <keyword id="9265502" type="UNKNOWN" weightage="20" keywordseo="vaccine-candidates">vaccine candidates</keyword> for <keyword id="8763838" type="UNKNOWN" weightage="20" keywordseo="covid-19">Covid-19</keyword> are under different stages of clinical trials which could be ready for authorisation in near future, <keyword id="9195433" type="COMPANY" weightage="20" keywordseo="the-ministry-of-health">the ministry of health</keyword> and family welfare informed in a press briefing on Tuesday. The union health ministry informed that the eight vaccines include Astrazeneca and Oxford university developed and Serum Institute of <keyword id="3658" type="COUNTRY" weightage="20" keywordseo="India">India</keyword> manufactured <keyword id="9617748" type="COMPANY" weightage="20" keywordseo="covishield">Covishield</keyword> , Covaxin by Bharat Biotech Limited, ZyCoV-D by Zydus Cadila, Russian vaccine candidate Sputnik-V, NVX-CoV2373 by SII, HGCO19 by Geneva, and two unlabeled vaccines  Recombinant Protein Antigen based vaccine by Biological E Limited  and Inactivated rabies vector platform by Bharat Biotech. While the former five vaccine candidates have entered either phase II or phase III clinical trials, the latter three are in pre-clinical trial phases, the ministry informed. Meanwhile, two vaccines candidates  Covishield and Covaxin  are in the third stage of clinical trials. They have applied for emergency use authorisation to the Drug Controller General of India (DCGI). Their application is pending for the review which is expected to happen on Wednesday by the subject expert committee (SEC) for the vaccines. However, the application for the emergency use authorisation (EUA) of <keyword id="10399185" type="LOCATION" weightage="20" keywordseo="covaxina">Covaxina</keyword> and Covishied has followed after Pfizer's BNT162b2 which was the first vaccine candidate to seek the EUA.Union health secretary Rajesh Bhushan informed that few of the vaccine candidates may receive license for authorisation in next few weeks. "The complete immunization in all the eight candidates would require 2-3 doses of it inoculated at the gap of 3 to 4 weeks," he added. He also cautioned that COVID precautions must be undertaken even after the vaccination Pfizer India had submitted an application on December 4 to the DCGI seeking emergency use authorisation (EUA) for its Covid-19 vaccine in India. Following which, Serum institute also filed for the EUA while the Bharat Biotech's applied for the same on Monday. Pfizer applied for EUA in India after it received permission for temporary authorisation for its emergency use in the UK last week. The UK on Wednesday became the first country to approve the Pfizer/BioNTech vaccine against COVID-19, with the UK regulator Medicines and Healthcare products Regulatory Agency granted approval to Pfizer's vaccine for EUA on Wednesday last week. Pfizer's vaccine would require -70 degree celsius of temperature for its storage. Experts have raised doubts that the extreme low temperature required for storing the vaccine poses a big challenge for its delivery in a country like India, especially in its smaller towns and rural areas where maintaining such cold chain facilities would be very difficult. SEE ALSO: <a href="https://www.businessinsider.in/business/telecom/news/mukesh-ambani-says-jio-will-rollout-5g-services-by-june-2021-and-it-will-go-beyond-india/articleshow/79619222.cms">Mukesh Ambani says Jio will rollout 5G services by June 2021 – and it will go beyond India</a> <a href="https://www.businessinsider.in/stock-market/news/top-stocks-to-watch-canara-bank-sun-pharma-titan-nbcc-gujarat-state-fertilizers-coffee-day-and-others/articleshow/79617464.cms">Top stocks to watch — Canara Bank, Sun Pharma, Titan, NBCC, Gujarat State Fertilizers, Coffee Day, and others</a>

India could have 8 vaccines ready for authorisation in near future

New Delhi, Dec 8 (IANS) From line-listing of prioritised groups, strengthening cold chain infrastructure to adding more vaccinators, the Union Health Ministry on Tuesday charted out list of preparatory activities which are being carried out by it in collaboration with states and union territories for roll-out of Covid-19 vaccine. Addressing the press conference, Health Ministry Secretary Rajesh Bhushan listed out six consultative process and five key strategies the government is adopting to roll out the most-awaited vaccination for the disease, which has wreaked havoc worldwide. The preparatory activities involves line-listing of prioritised population groups for Covid-19 vaccination, multi-level coordination mechanism, strengthening of cold chain infrastructure, additional vaccinators, communication strategy on vaccine safety, effectiveness etc and Co-WIN, a digital platform for vaccination delivery. Health Ministry Secretary said that 30 crore people have been listed on prioritised population groups, which involves one crore of healthcare workers, two crores personnel from police department, armed forces, home guard, civil defence organisation and 27 crore people above age of 50 and below 50 with comorbidities. Secondly, the vaccines are temperature sensitive and need to be stored in specific temperature and hence cold chain system consists of 85,634 equipments for storage of vaccine at about 28,947 cold chain points across the country presently. "The current cold chain is capable of storing additional quantity of Covid-19 vaccine required for first 3 Crore i.e. health care Workers and front-line Workers," said Bhushan. The Union Health Ministry also said that as many as 1.54 lakh vaccinators or auxiliary nurse midwifes will administer Covid-19 vaccine to people under the universal immunization programme when the vaccination process begins. Besides this, key strategies involve orderly, smooth implementation driven by technology, no compromise of existing healthcare services, especially national programmes and primary care, utilisation of experience of elections and universal immunization programme, ensuring people's participation and no compromise on scientific and regulatory norms, As many as eight vaccine candidates for COVID-19 are under different stages of clinical trials which could be ready for authorisations in near future. It includes Astrazeneca and Oxford university developed and Serum Institute of India manufactured Covishield, Covaxin by Bharat Biotech Limited, ZyCoV-D by Zydus Cadila, Russian vaccine candidate Sputnik-V, NVX-CoV2373 by SII, HGCO19 by Geneva, and two unlabeled vaccines-Recombinant Protein Antigen based vaccine by Biological E Limited-and Inactivated rabies vector platform by Bharat Biotech. Meanwhile, two vaccines candidates - Covishield and Covaxin - are in the third stage of clinical trials. They have applied for emergency use authorisation to the Drug Controller General of India (DCGI). Their application is pending for the review which is expected to happen on Wednesday by the subject expert committee (SEC) for the vaccines. However, the application for the emergency use authorization (EUA) of Covaxina and Covishied has followed after Pfizer's BNT162b2 which was the first vaccine candidate to seek the EUA. -- IANS aka/ash

You Searched For "covaxina" and got 2 results

India could have 8 vaccines ready for authorisation in near future

IANS

Health Ministry charts out preparatory activities for Covid-19 vaccine roll-out

IANS

Popular Keywords

Buying Guides